Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs THPy Sequencing in HER2+ Breast Cancer Brain Metastases
NCT06975475Phase 2Not yet recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan in HER2-positive breast cancer. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06975475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975475.